A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)

Smyth, E, Rowley, S, Allum, W et al. (17 more authors) (2016) A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology, 27 (suppl_6). LBA26. ISSN 0923-7534

Metadata

Authors/Creators:
Dates:
  • Published (online): 13 October 2016
  • Published: 1 October 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 27 Nov 2018 14:46
Last Modified: 27 Nov 2018 14:46
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdw435.17

Share / Export

Statistics